Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)

NCT02231749 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1390

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Renal Cell Carcinoma
Metastatic Renal Cell Carcinoma

Interventions

BIOLOGICAL: Nivolumab
BIOLOGICAL: Ipilimumab
DRUG: Sunitinib

Sponsor

Bristol-Myers Squibb

Collaborators

[object Object]